{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:19:35Z","timestamp":1792279175286,"version":"4.4.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Anti-tumour necrosis factor [anti-TNF] induced skin reactions are common adverse events in paediatric inflammatory bowel disease [IBD]. We aimed to report on outcomes of children with anti-TNF induced skin reactions who switched to ustekinumab [UST] vs. continued anti-TNF therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Charts were reviewed for paediatric IBD patients with anti-TNF induced skin reactions. Skin reactions, including psoriasiform dermatitis [PD], were classified as mild or severe based on a severity score. Primary outcome was frequency of skin resolution at 6 months. Secondary outcomes were combined clinical remission and skin resolution at 6 months and skin resolution at latest follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 111\/638 [17%] children ([85, 21%] infliximab [IFX]; [26, 11%] adalimumab [ADA]) developed skin reactions. Eighty [72%] had PD, 25 [23%] infections, and four [4%] alopecia areata; 71 [64%] continued anti-TNF; and 40 [36%] switched to UST. In all, 73 [66%] had severe reactions and were more likely to switch to UST than if mild (37 [51%] vs. 3 [8%]; p &amp;lt;0.0001). Switching to UST had a higher rate and odds of resolution (29 [73%] vs. 24 [34%]; p &amp;lt;0.0001; odds ratio [OR] = 19.7, 95% confidence interval [CI]: 5.6, 69.5; p &amp;lt;0.0001) and combined remission (21 [52%] vs. 22 [31%]; p = 0.03; OR = 8.5, 95% CI: 2.5, 28.4; p = 0.0005] vs. continuing anti-TNF at 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Children who switched to UST after anti-TNF induced skin reactions were more likely to have improved outcomes than those who continued anti-TNF therapy. Future studies are needed to determine immune mechanisms of anti-TNF induced skin reactions and treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjac055","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T12:26:52Z","timestamp":1649334412000},"page":"1420-1427","source":"Crossref","is-referenced-by-count":20,"title":["Outcomes of Children with Inflammatory Bowel Disease who Develop Anti-tumour Necrosis Factor-induced Skin Reactions"],"prefix":"10.1093","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9023-4948","authenticated-orcid":false,"given":"Michael T","family":"Dolinger","sequence":"first","affiliation":[{"name":"Department of Pediatric Gastroenterology, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Rolfes","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Spencer","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Stoffels","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dunkin","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai , New York, NY , USA"},{"name":"Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla C","family":"Dubinsky","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"2022090816394852100_CIT0001","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children.","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"2022090816394852100_CIT0002","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.","volume":"10","author":"Hyams","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022090816394852100_CIT0003","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe Crohn\u2019s disease in children.","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"key":"2022090816394852100_CIT0004","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1053\/j.gastro.2013.10.027","article-title":"Increased effectiveness of early therapy with anti-tumour necrosis factor-\u03b1 vs an immunomodulator in children with Crohn\u2019s disease.","volume":"146","author":"Walters","year":"2014","journal-title":"Gastroenterology"},{"key":"2022090816394852100_CIT0005","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/apt.15094","article-title":"Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood.","volume":"49","author":"Ashton","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2022090816394852100_CIT0006","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/ecco-jcc\/jjz019","article-title":"Intensified infliximab induction is associated with improved response and decreased colectomy in steroid-refractory paediatric ulcerative colitis.","volume":"13","author":"Church","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2022090816394852100_CIT0007","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1002\/ibd.21643","article-title":"Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients.","volume":"17","author":"Baumgart","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2022090816394852100_CIT0008","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.crohns.2013.10.013","article-title":"The association of psoriasiform rash with anti-tumour necrosis factor [anti-TNF] therapy in inflammatory bowel disease: a single academic centre case series.","volume":"8","author":"Afzali","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2022090816394852100_CIT0009","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/MIB.0000000000000088","article-title":"Skin reactions during anti-TNF\u03b1 therapy for pediatric inflammatory bowel disease: a 2-year prospective study.","volume":"20","author":"M\u00e4lk\u00f6nen","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2022090816394852100_CIT0010","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/ajg.2015.205","article-title":"Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.","volume":"110","author":"Fr\u00e9ling","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2022090816394852100_CIT0011","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1155\/2015\/428702","article-title":"A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.","volume":"29","author":"Huang","year":"2015","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2022090816394852100_CIT0012","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.13352","article-title":"Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.","volume":"42","author":"Pugliese","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2022090816394852100_CIT0013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M15-0729","article-title":"Characteristics of skin lesions associated with anti-tumour necrosis factor therapy in patients with inflammatory bowel disease: a cohort study.","volume":"164","author":"Cleynen","year":"2016","journal-title":"Ann Intern Med"},{"key":"2022090816394852100_CIT0014","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3109\/00365521.2015.1125524","article-title":"Infliximab-induced skin manifestations in patients with inflammatory bowel disease.","volume":"51","author":"Hellstr\u00f6m","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"2022090816394852100_CIT0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/MPG.0000000000002349","article-title":"Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease.","volume":"69","author":"Courbette","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2022090816394852100_CIT0016","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/1203475420917387","article-title":"Skin manifestations in pediatric patients treated with a TNF-alpha inhibitor for inflammatory bowel disease: a retrospective study [formula: see text].","volume":"24","author":"Cossio","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"2022090816394852100_CIT0017","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/pde.13081","article-title":"Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumour necrosis factor alpha agents.","volume":"34","author":"Eickstaedt","year":"2017","journal-title":"Pediatr Dermatol"},{"key":"2022090816394852100_CIT0018","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1093\/ibd\/izy112","article-title":"Dermatological manifestations in pediatric patients with inflammatory bowel diseases on anti-TNF therapy.","volume":"24","author":"Sridhar","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2022090816394852100_CIT0019","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/apt.13542","article-title":"Genetic basis of TNF-a antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis.","volume":"43","author":"Vedak","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2022090816394852100_CIT0020","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40257-017-0296-7","article-title":"Clinical signs, pathophysiology and management of cutaneous side effects of anti-tumour necrosis factor agents.","volume":"18","author":"Segaert","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"2022090816394852100_CIT0021","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jid.2018.07.029","article-title":"Incidence and risk of inflammatory bowel disease in patients with psoriasis: a nationwide 20-year cohort study.","volume":"139","author":"Egeberg","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2022090816394852100_CIT0022","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1084\/jem.20061308","article-title":"Interleukin [IL]-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides.","volume":"203","author":"Liang","year":"2006","journal-title":"J Exp Med"},{"key":"2022090816394852100_CIT0023","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment.","volume":"63","author":"Tillack","year":"2014","journal-title":"Gut"},{"key":"2022090816394852100_CIT0024","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ibd.20315","article-title":"Linking genetic susceptibility to Crohn\u2019s disease with Th17 cell function: IL-22 serum levels are increased in Crohn\u2019s disease and correlate with disease activity and IL23R genotype status.","volume":"14","author":"Schmechel","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"2022090816394852100_CIT0025","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/annrheumdis-2012-202143","article-title":"Psoriasis, psoriatic arthritis and increased risk of incident Crohn\u2019s disease in US women.","volume":"72","author":"Li","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022090816394852100_CIT0026","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.clindermatol.2007.08.006","article-title":"Comorbidities in psoriasis.","volume":"25","author":"Christophers","year":"2007","journal-title":"Clin Dermatol"},{"key":"2022090816394852100_CIT0027","first-page":"962","article-title":"Increased occurrence of psoriasis in patients with Crohn\u2019s disease and their relatives.","volume":"85","author":"Lee","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"2022090816394852100_CIT0028","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/ajg.2009.496","article-title":"Familial association of inflammatory bowel diseases with other autoimmune and related diseases.","volume":"105","author":"Hemminki","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2022090816394852100_CIT0029","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","article-title":"Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci.","volume":"90","author":"Ellinghaus","year":"2012","journal-title":"Am J Hum Genet"},{"key":"2022090816394852100_CIT0030","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ng.3528","article-title":"Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci.","volume":"48","author":"Ellinghaus","year":"2016","journal-title":"Nat Genet"},{"key":"2022090816394852100_CIT0031","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","article-title":"Tumour necrosis factor-\u03b1 inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience.","volume":"76","author":"Brown","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2022090816394852100_CIT0032","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/1346-8138.14816","article-title":"Ustekinumab for skin reactions associated with anti-tumour necrosis factor-\u03b1 agents in patients with inflammatory bowel diseases: a single-center retrospective study.","volume":"46","author":"Ezzedine","year":"2019","journal-title":"J Dermatol"},{"key":"2022090816394852100_CIT0033","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3390\/jcm10051040","article-title":"Cutaneous manifestations in biological-treated inflammatory bowel disease patients: a narrative review.","volume":"10","author":"Lambert","year":"2021","journal-title":"J Clin Med"},{"key":"2022090816394852100_CIT0034","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MPG.0000000000002362","article-title":"Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center.","volume":"69","author":"Dayan","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2022090816394852100_CIT0035","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1111\/pde.13138","article-title":"Efficiency of ustekinumab in Crohn\u2019s disease with severe psoriasiform rash induced by biotherapies in an adolescent.","volume":"34","author":"Bertrand","year":"2017","journal-title":"Pediatr Dermatol"},{"key":"2022090816394852100_CIT0036","doi-asserted-by":"crossref","first-page":"328","DOI":"10.36849\/JDD.2020.2106","article-title":"Tumour necrosis factor inhibitor-induced psoriasis in a pediatric Crohn\u2019s disease patient successfully treated with ustekinumab.","volume":"19","author":"Bonomo","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"2022090816394852100_CIT0037","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification.","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2022090816394852100_CIT0038","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/MCO.0000000000000399","article-title":"Whats \u2018App-ening\u2019: the help of new technologies in nutrition in digestive diseases.","volume":"20","author":"Ankersen","year":"2017","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"2022090816394852100_CIT0039","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis.","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"2022090816394852100_CIT0040","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2340\/00015555-2636","article-title":"Pattern and severity of psoriasiform eruptions in patients with inflammatory bowel diseases, arthritis or skin inflammatory disorders treated with TNF-alpha inhibitors.","volume":"97","author":"Darrigade","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2022090816394852100_CIT0041","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41586-021-03188-w","article-title":"Skin-resident innate lymphoid cells converge on a pathogenic effector state.","volume":"592","author":"Bielecki","year":"2021","journal-title":"Nature"},{"key":"2022090816394852100_CIT0042","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jdv.16246","article-title":"Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.","volume":"34","author":"Al-Janabi","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2022090816394852100_CIT0043","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"2022090816394852100_CIT0044","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease [STRIDE] initiative of the International Organization for the Study of IBD [IOIBD]: determining therapeutic goals for treat-to-target strategies in IBD.","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjac055\/43679529\/jjac055.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/9\/1420\/45747621\/jjac055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/9\/1420\/45747621\/jjac055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T19:14:12Z","timestamp":1675192452000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/16\/9\/1420\/6564796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,4,7]]},"published-print":{"date-parts":[[2022,9,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac055","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,4,7]]}}}